medRxiv preprint doi: https://doi.org/10.1101/2020.10.22.20217851; this version posted October 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1

1 Title

2 Clinical and laboratory characteristics in outpatient diagnosis of COVID-19 in healthcare

3 professionals in Rio de Janeiro, Brazil

4 Luís Cristóvão Porto^{1,2a}, Claudia Henrique da Costa³, Alessandra Sant'Anna Nunes⁴, Isabel 5 Bouzas⁵, Tiago C. Ferreira⁶, Vinicius M. Porto², Danielle A. Secco¹, Sandra P. C. Vilas Boas², Anamelia C. Faria³, Rosangela A. G. Marins⁷, Cíntia A. Duarte⁴, Elizabeth P. Bittencourt⁸, 6 Anderson V. Loureiro⁹, Angela Maria G. Santos¹, Vania Maria A. Souza², Fernanda H. Silva⁴, 7 Maria Cristina Lopes², Marcelle V. Castro¹, Areta D. Silva², Flavia M. Vasconcelos², Diego S. 8 9 Moreira⁴, Juliana P. Motta¹, Cristiano V. Lima², Raphaela S. Menezes¹, Nathalia B. V. Brazão¹, 10 Jeane S. Nogueira¹, Ana Paula Villela Silva¹, Ingrid A.A. Brito¹, Scarlathe B. Costa¹, Roberta Mariana R. Lemes¹, Jessica Isis O. dePaula¹, Giovanna L. Bongionanni¹, Ohana C. L. Bezerra¹, 11 Valter V. Andrade-Neto¹, Leonardo Morette², Rafael S. Barbosa¹⁰, Jose Afonso L. Sanches¹⁰, 12 Pedro L. Melo¹¹, Sergio M. Freire¹², Romulo Souza¹³, Laiz Gomes⁵, Denize P. Felizardo⁸, 13 Alexsandre V. Rodrigues⁸, Priscila A. Franco¹³, Renata Miranda¹³ and Rogerio Rufino³ 14 1. Histocompatibility and Cryopreservation Laboratory, Institute of Biology Roberto 15 16 Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, 20950-003 17 Clinical Pathology Service, Polyclinic Piquet Carneiro, Rio de Janeiro State University, Rio 2. 18 de Janeiro, 20950-003 19 3. Department of Pulmonology and Tisiology, Faculty of Medical Sciences and Service of 20 Pulmonology, Polyclinic Piquet Carneiro, Rio de Janeiro State University, Rio de Janeiro, 21 20950-003 22 4. Nurse Department, Polyclinic Piquet Carneiro, Rio de Janeiro State University, Rio de 23 Janeiro, 20950-003 24 5. Health Research Support Facility Center (CAPCS), Polyclinic Piquet Carneiro, Rio de 25 Janeiro State University, Rio de Janeiro, 20950-003 26 6. Infectology Service, Polyclinic Piquet Carneiro, Rio de Janeiro State University, Rio de 27 Janeiro, 20950-003 28 7. Research Division, Clementino Fraga Filho University Hospital, Federal University of Rio 29 de Janeiro, Rio de Janeiro, 21941-590 30 8. Administrative and Finance Services, Polyclinic Piquet Carneiro, Rio de Janeiro State 31 University, Rio de Janeiro, 20950-003 32 9. Pharmacy and Supply Service, Polyclinic Piquet Carneiro, Rio de Janeiro State University, 33 Rio de Janeiro, 20950-003 34 10. Logistic, Informatic and Infrastructure Service, Polyclinic Piquet Carneiro, Rio de Janeiro 35 State University, Rio de Janeiro, 20950-003 36 11. Laboratory of Biomedical Instrumentation, Institute of Biology Roberto Alcantara Gomes, 37 Rio de Janeiro State University, Rio de Janeiro, 20550-013 38 12. Information Technology and Education in Health Department, Faculty of Medical 39 Sciences, Rio de Janeiro State University, Rio de Janeiro, 20551-031 40 13. Communication and Human Resource Service, Polyclinic Piquet Carneiro, Rio de Janeiro 41 State University, Rio de Janeiro, 20950-003 42

43 Running Title

44 COVID-19 in RJ Healthcare Professionals

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Abstract: 164 words

2 Text: 2998 words

1 Footnote page

- 2 Authors have no disclosure or a conflict of interest.
- 3 This study was partly supported with grants from Rio de Janeiro Research Agency (FAPERJ - E-
- 4 26/202.683/2019 and E-26/210.092/2018) and Conselho Nacional de Pesquisas (CNPq -
- 5 309881/2018-8).

6 **Corresponding author**

- 7 Luís Cristóvão Porto, MD, ScD
- 8 **Full Professor UERJ**
- 9 Laboratory of Histocompatibility and Cryopreservation
- 10 Rio de Janeiro State University
- Av Marechal Rondon 381 11
- 12 20950-003
- 13 Rio de Janeiro Brazil
- 14 Tel/fax 55 21 23342426
- 15 lcporto@uerj.br
- 16 Summary
- 17 From March 19 to April 8 2020, 1,297 patients attended the Polyclinic Piquet Carneiro for
- 18 COVID-19 detection. Healthcare professional data was analyzed, significant clinical features
- 19 were anosmia, fever, chills and body pain. Elevated CRP, leukopenia and monocytosis were
- 20 common in COVID-19.

Abstract 1

- 2 Aims: This study aimed to identify the symptoms associated with early stage SARS-CoV-2
- 3 (COVID-19) infections in healthcare professionals (HCP) using both clinical and laboratory data.
- 4 Methods: A total of 1,297 patients, admitted between March 18 and April 8, 2020, were
- 5 stratified according to their risk of developing COVID-19 using their responses to a
- 6 questionnaire designed to evaluate symptoms and risk conditions.
- 7 Results: Anosmia/hyposmia (p < 0.0001), fever (p < 0.0001), body pain (p < 0.0001), and chills
- 8 (p=0.001) were all independent predictors for COVID-19, with a 72% estimated probability for
- 9 detecting COVID-19 in nasopharyngeal swab samples. Leukopenia, relative monocytosis,
- 10 decreased eosinophil values, CRP, and platelets were also shown to be significant independent
- 11 predictors for COVID-19.
- 12 Conclusions: The significant clinical features for COVID-19 were identified as anosmia, fever,
- 13 chills, and body pain. Elevated CRP, leukocytes under 5,400 x 10⁹/L, and relative monocytosis
- 14 (>9%) were common among patients with a confirmed COVID-19 diagnosis. These variables
- 15 may help, in the absence of RT-PCR tests, to identify possible COVID-19 infections during
- 16 pandemic outbreaks.
- 17 Keywords: diagnosis, leukocytes, biochemistry, COVID-19, healthcare professionals, leukocytes,
- 18 anosmia, body pain, C-reactive protein, monocytes, fever, chills

19

5

1 INTRODUCTION

2	The coronavirus disease 2019 (COVID-19) pandemic caused by the outbreak of the novel severe
3	acute respiratory syndrome coronavirus-2 (SARS-CoV-2) represents a significant and urgent
4	threat to global health. By October 6, 2020, Brazil ranks third in the number of COVID-19 cases
5	(4,927,235) and second in number of deaths (146,675) in the world {University, 2020 #1800}.
6	Outbreaks of this magnitude lead to significant increases in demand for hospital beds, medical
7	equipment, and human resources. Additionally, healthcare professionals (HCP) working on the
8	frontline are amongst the groups most affected by the pandemic - in Italy, for example, 20% of
9	these HCP were affected by COVID-19,[2] contributing to an even greater burden on the health
10	system. Despite public health responses aimed at containing the disease and delaying its spread,
11 12	several countries have been challenged with an intensive care crisis, and this crisis is imminent in Brazil. In this context, attention to the health and wellbeing of HCP is essential to maintain
12	the integrity and functionality of the health system which allows for both population care and
13	pandemic surveillance.
14	
15	In this study, we investigated the clinical features of 1,297 individuals, mostly HCP (80%),

associated with the presence of the SARS-CoV-2 (COVID-19) during the period immediately
following the declaration of the pandemic in Brazil.

18

1 MATERIALS AND METHODS

2 Patient selection and characteristics

3 A total of 1,297 individuals visited the Piquet Carneiro Polyclinic at the Rio de Janeiro State 4 University (UERJ), a designated diagnostic site for personnel working in the Brazilian public 5 health system, for screening of COVID-19 between March 19 and April 8, 2020. Here, they found 6 three levels of assistance. First, both HCP and clinical patients were asked to identify their 7 general symptoms. Following this, asymptomatic patients and HCP who had appointments 8 scheduled at various specialized clinics were provided with a white bracelet and allowed to enter 9 the medical center for their consultation. Then, symptomatic patients were referred to the care 10 of the nursing and medical teams. All patients with dyspnea, high fever, chest pain, abnormal 11 pulmonary auscultation were then prescribed chest ultrasound to identify if hospital admission 12 was necessary. Individuals were then immediately assigned to various clinical grades in 13 accordance with those patients who presented with a fever (>37.5 $^{\circ}$ C) or poor O₂ saturation 14 (<94%) and were assigned yellow or red bracelets. After this evaluation, patients with red 15 bracelets were directed to the hospital when necessary and the rest of the patients were asked to complete the interview questionnaire. They received the necessary medical assistance and 16 17 laboratory samples were collected. All patients with yellow or red bracelets received a full 18 clinical and laboratory screening.

19 The questionnaire was used to identify high-risk comorbidities, influenza vaccine status, and to 20 facilitate the contact tracing over the previous two weeks (Table 1). Signs and symptoms, 21 nasopharyngeal swabs (NPS), and blood samples for the complementary biochemistry (n=1,297)22 and hematology tests (n=1,211) were also collected from all the patients. This study was 23 approved by the Local and National Ethics Committee (CAAE: 30135320.0.0000.5259).

24

7

- 1 Table 1. Characteristics of individuals attended for COVID-19 detection from March 18 to April
- 2 8, 2020 at Polyclinic Piquet Carneiro, Rio de Janeiro

	НСР	Non-HCP	Total	Р
N	1,001	266	1,297	
Female n (%)	755 (58.2)	155 (75.4)	910 (71.8)	<0.0001
Age (x ± SD)	41.3 ± 10.6	42.4 ± 11.8		0.956
BMI median [25-75]	26.5 [23.8-30.4]	28.3 [24.7-33.2]		0.0009
Color-Race n (%)	935	244	1,179	
White	532 (56.9)	99 (40.6)	631 (53.5)	0.0004
Brown	248 (26.5)	85 (34.8)	333 (28.2	
Black	135 (14.4)	55 (22.5)	190 (16.1)	
Asian	11 (1.2)	3 (0.1)	14 (1.2)	
Not-declared	8 (0.8)	2 (0.1)	10 (0.8)	
Indigenous	1 (0.0)	0 (0	1 (0.0)	
Education n (%)	953	243	1,369	
Less 9y	3 (3.1)	36 14.8)	39 (3.3)	<0.0001
9-12y	185 (19.4)	92 (37.9)	277 (23.2)	
12-16y	355 (37.2)	85 (35.0)	440 (36.8)	
>16y	410 (43.0)	30 (12.3)	440 (36.8)	
Vaccine status				
Influenza vaccine in 2019	636 (76.0)	114 (61.9)	750 (73.5)	<0.0001
Influenza vaccine in 2020	375 (47.7)	53 (31.1)	428 (44.8)	<0.0001
Medical History n (%)	1,001	266	1,297	
Arterial Hypertension	180 (17.9)	65 (24.4)	245 (19.3)	0.012
Medicine drugs (in use)	154 (15.3)	28 (10.5)	182 (14.3)	0.025
Chronic Sinusitis	81 (8.0)	36 (13.5)	117 (9.2)	0.006
Asthma	86 (8.5)	18 (6.7)	104 (8.2)	0.203
Contraceptives (n=1052)	78 (10.3)	22 (14.1)	100 (10.9)	0.106
Diabetes	58 (5.7)	20 (7.5)	78 (6.1)	0.184
Tobacco use	44 (4.4)	29 (10.9)	73 (5.7)	<0.0001
Obesity	42 (4.2)	30 (11.2)	72 (5.6)	<0.0001
Chronic bronchitis	50 (5.0)	14 (5.2)	64 (5.0)	0.481
Alcohol addiction	47 (4.7)	7 (2.6)	54 (4.2)	0.090
Hypothyroidism	43 (4.3)	3 (1.1)	46 (3.6)	0.007
Cardiovascular disease	19 (1.9)	6 (2.2)	25 (1.9)	0.432
Tuberculosis	10 (1.0)	4 (1.5)	14 (1.1)	0.336
Mental diseaseL	4 (0.4)	4 (1.5)	8 (0.6)	0.065
Neoplasia	5 (0.5)	1 (0.3)	6 (0.4)	0.631
Liver Disease	3 (0.3)	3 (1.1)	6 (0.4)	0.111
Rheumatoid Arthritis	5 (0.5)	0 (0)	5 (0.3)	0.307

3 HCP – Healthcare professionals, Non-HCP – non-Healthcare personnel. BMI – body mass index.

4 Data <expressed as mean+- SD, compared with ANOVA or median [25%-75%].

8

1 Real-time PCR SARS-COV-2 detection and laboratory testing

2 RNA was extracted from the samples according to both the COVID-19 infection and laboratory 3 detection for the SARS-COV-2 guidelines [12]. Specific real-time reverse transcription 4 polymerase chain reaction (RT-PCR) assays were performed using commercial kits or previously 5 designed nCoVqRT-PCR kits (Biomanguinhos, Fiocruz, Rio de Janeiro, and Instituto de Biologia 6 Molecular do Paraná, Paraná) approved by the Brazilian Vigilance (ANVISA) group within the 7 Histocompatibility and Cryopreservation Laboratory at UERJ. 8 Peripheral blood tests were performed by the Pathology Service of the Piquet Carneiro Polyclinic 9 using several automated systems. The complete blood counts were carried out using a SYSMEX 10 XT1800i, while the C-reactive protein (CRP; immunoturbidimetric), creatinine (CR, picrate 11 kinetic), lactate dehydrogenase (LDH; IFCC), aspartate and alanine aminotransferases (AST and 12 ALT; NAPH), and creatine phosphokinase (CK; N-acetyl L-cysteine) assays were performed using

13 the Architect c8000 Equipment from Abbott.

14 Data collection

All the questionnaire, nursing and medical consultation records, and laboratory findings were added to the electronic media files for each patient. This data was then used to ascertain the epidemiological and symptom data for the larger cohort. All data were checked by two independent physicians (LCP and IB).

19 Statistical analysis

The quantitative peripheral blood tests were compared using ANOVA or the Mann-Whitney U test and the Kruskal Wallis tests when appropriate. The categorical variables were expressed as numbers (%) and compared using the Fisher's exact test. Differences were considered significant at a p-value of < 0.05 using a one-tailed test. Tukey or Dunn test was applied when multiple comparisons were analyzed, respectively for normal or nonparametric variables. The date of testing was also grouped by week. In the multivariate analyses, Binary Logistic Regression (LR)

9

- 1 was used to identify the clinical, laboratory and independent signs or symptoms that could
- 2 explain (or predict) the presence of the SARS-COV-2 in each sample. The selection process was
- 3 applied using a stepwise process which allowed us to select the smallest subgroup of
- 4 independent variables that best explained any particular outcome. All analyses were performed
- 5 using the SPSS 26.0 software.

6 **RESULTS**

- 7 Demographic and laboratory characteristics linked to positive COVID-19 test results
- 8 Risk factors related to the COVID-19 NPS results are summarized in Tables 2 and 3.

9 **Table 2**. Medical history and vaccine status from COVID-19 nasopharyngeal swab individuals

10 attended from March 18 to April 8, 2020 at Polyclinic Piquet Carneiro, Rio de Janeiro

	Total	Positive	Inconclusive	Undetected	p#
Vaccine Status n (%)					
Influenza vaccine in 2019	750 (73.5)	273 (73.5)	61 (75.3)	416 (73.2)	0.925
Influenza vaccine in 2020	428 (44.8)	188 (51.6)	36 (51.4)	204 (39.1)	0.001
Medical history n (%)	1,267	410 (32.4)	94 (7.4)	763 (60.2)	
Arterial Hypertension	245 (19.3)	94 (22.9)	15 (15.9)	136 (17.8)	0.075
Medicine drugs (in use)	182 (14.3)	80 (19.5)	15 (15.9)	87 (11.4)	0.001
Chronic Sinusitis	117 (9.2)	25 (6.1)	8 (8.5)	84 (11.0)	0.021
Asthma	104 (8.2)	26 (6.3)	10 (10.6)	68 (8.9)	0.209
Contraceptives (n=910)	100 (10.9)	31 (10.2)	10 (13.7)	59 (11.0)	0.689
Diabetes	78 (6.1)	29 (7.0)	5 (5.3)	44 (5.7)	0.634
Tobacco use	73 (5.7)	11 (2.6)	4 (4.2)	58 (7.6)	0.002
Obesity	72 (5.6)	24 (5.8)	6 (6.3)	42 (5.5)	0.926
Chronic Bronchitis	64 (5.0)	19 (4.6)	7 (7.4)	38 (4.9)	0.527
Alcohol addiction	54 (4.2)	22 (5.3)	4 (4.2)	28 (3.6)	0.391
Hypothyroidism	46 (3.6)	13 (3.1)	6 (6.3)	27 (3.5)	0.316
Cardiovascular disease	25 (1.9)	6 (1.4)	2 (2.1)	17 (2.2)	0.664
Tuberculosis	14 (1.1)	0	1 (1.0)	13 (1.7)	0.029
Mental disease	8 (.6)	5 (1.2)	0	3 (.3)	0.170
Neoplasia	6 (.4)	1 (.2)	0	5 (.6)	0.487
Liver disease	6 (.4)	0	0	6 (.7)	0.137
Rheumatoid arthritis	5 (.3)	1 (0.2)	0	4 (.5)	0.626

11 # - X2 test. **a-** Detected vs Undetected. **b-** Detected vs Inconclusive and **c-** Undetected vs

12 Inconclusive (p<0.05).

10

Table 3. Age, signs and symptoms from COVID-19 nasopharyngeal swab individuals attended from March 18 to April

2 8, 2020 at Polyclinic Piquet Carneiro, Rio de Janeiro

1

	Total	Detected	Inconclusive	Undetected	Р
Age (years)	1,267	40.5 [34-49] (n=410)	40 [34-50] (n=94)	39 [33-50] (n=763)	0.687
Temperature	1,010	36.8±0.8 (n=378)	36.6±0.8 (n=86)	36.5±0.8 (n=546)	0.383
Symptoms (days) m Q1-Q3	1,170	5 (4-7) (n=394)	6 (4-7) (n=91)	6 (4-8) (n=685)	<0.0001ª
BMI	926	28.3±5.5 (n=314)	27.5±5.8 (n=69)	27.6±5.4 (n=543)	0.191
Respiratory Frequency	552	17.8±2.9 (n=176)	17.6±2.9 (n=38)	17.8±2.9 (n=338)	0.854
O2 saturation	1,194	97.5±1.6 (n=396)	97.7±1.4 (n=90)	97.6±1.5 (n=708)	0.557
Cardiac Frequency	851	86.1±14.6 (n=364)	85.9±15.2 (n=71))	84.9±14.8 (n=416)	0.554
Suspected Contact with Infected	866 (72.8)	301 (77.6)	69 (78.4)	496 (69.6)	0.008
Contagious suspect days m Q1-Q3	708	7 [5.5-10] (n=256)	8 [7-10] (n=555)	8 [6-12] (n=397)	0.060
Confirmed Contact with Infected	471 (40.6)	170 (43,8)	43 (46,7)	258 (38,0)	0.081
Contagious confirmed days m Q1-Q3	428	8 [6-10] (n=157)	8 [7-10] (n=38)	10 [7-13] (n=233)	0.077
Symptoms n (%)					
Cough	1,021 (80.5)	343 (83.6)	77 (81.9)	601 (78.7)	0.123
Headache	880 (69.4)	310 (75.6)	69 (73.4)	501 (65.6)	0.001
Body ache	800 (63.1)	318 (77.5)	76 (80.8)	406 (53.2)	<0.0001ª
Fever	711 (56.1)	291 (70.9)	59 (62.7)	361 (47.3)	<0.0001ª
Sore throat	666 (52.5)	193 (47.0)	41 (43.6)	432 (56.6)	0.001
Coryza	650 (51.3)	193 (47.0)	41 (43.6)	416 (54.5)	0.015
Tiredness	618 (48.7)	203 (49.5)	58 (61.7)	357 (46.7)	0.022
Sneeze	527 (41.5)	164 (40.0)	36 (38.3)	327 (42.8)	0.509
Nasal congestion	517 (40.8)	176 (42.9)	40 (42.5)	301 (39.4)	0.481
Prostration	424 (33.4)	152 (37.0)	34 (36.1)	238 (31.1)	0.106
Respiratory difficulty	346 (27.3)	94 (22.9)	30 (31.9)	222 (29.1)	0.045
Diarrhoea	337 (26.6)	123 (30.0)	21 (22.3)	193 (25.2)	0.137
Anosmia or Hyposmia	311 (24.5)	157 (38.2)	31 (32.9)	123 (16.1)	<0.0001ª
Chill	239 (18.8)	118 (28.7)	22 (23.4)	99 (12.9)	<0.0001ª
Anxiety	215 (16.9)	56 (13.6)	24 (25.5)	135 (17.6)	0.015
Nausea or Vomiting	166 (13.1)	80 (19.5)	18 (19.1)	68 (8.9)	<0.0001ª
Eye conjuntiva congestion	147 (11.6)	41 (10.0)	9 (9.5)	97 (12.7)	0.735
Palpitation	147 (11.6)	45 (10.9)	13 (13.8)	89 (11.6)	0.313
Irritability	104 (8.2)	34 (8.2)	9 (9.5)	61 (7.9)	0.868
Abdominal pain	102 (8.0)	49 (11.9)	9 (9.5)	44 (5.7)	0.0009
Sputum production	66 (5.2)	32 (7.8)	2 (2.1)	32 (4.1)	0.011
Swallow difficulty	44 (3.4)	18 (4.3)	6 (6.3)	20 (2.6)	0.079
Mental confusion	25 (1.9)	7 (1.7)	2 (2.1)	16 (2.1)	0.895
Lymph node enlargement	25 (1.9)	4 (0.9)	1 (1.0)	20 (2.6)	0.124
Skin rash	14 (1.1)	7 (1.7)	1 (1.0)	6 (0.7)	0.355

3 # - X2 test. or Data expressed as mean+- SD. compared with ANOVA or by median and interquartile (m Q1-Q3) and

4 compared with Kruskal-Wallis test and Tukey or Dunn tests for multiple comparison. a- Detected vs Undetected. b-

5 Detected vs Inconclusive and c- Undetected vs Inconclusive (p<0.05).

11

Cough, headache, body ache (including myalgia at rest or during minimal physical effort), fever, sore throat, coryza, and tiredness were common symptoms, present in more than a third of the patients in the cohort. These symptoms were common to both the undetected, inconclusive, and SARS-COV-2-positive groups. However, chills, anosmia or hyposmia, nausea or vomiting, and abdominal pain, although less frequent, were more common in individuals with the SARS-COV-2-positive results (p<0.001) than in patients with no detectable infection.

The respiratory and cardiac frequencies, temperature, O₂ saturation, and laboratory results for this cohort are summarized in Table 4. CRP, LDH, AST, and ALT levels were all shown to be elevated in COVID-19 patients, while leukometry values were shown to differ between individuals regardless of the SARS-COV-2 SNF detection result.

When we applied the logistic regression, we observed that anosmia/hyposmia (OR: 2.38, 95%IC: 1.78-3.19, p < 0.0001), fever (OR: 2.13, 95%IC: 1.63-2.79, p < 0.0001), body pain (OR: 2.11, 95%IC: 1.59-2.82, p < 0.0001), and chills (OR: 1.70, 95%IC: 1.23-2.34, p = 0.001), in this specific order, were independent predictors for COVID-19. The other signs and symptoms did not make a significant contribution, when evaluated using the 95% confidence interval. The estimated probability of COVID-19 detection in patients presenting with these four signs and symptoms (fever, body pain, anosmia-hyposmia, and chills) was 72% when evaluated using a model adjusted for logistic regression.

When the laboratory test results (906 complete records) were evaluated using logistic regression leukocytes (p<0.0001), monocytes (p<0.0001), eosinophils (p<0.0001), CRP (p=0.001), and platelets (p=0.003), in this specific order, were significant independent predictors for COVID-19. The other laboratory variables did not make a significant contribution to predicting a SARS-CoV-2 positive sample at 95% confidence interval.

For the final model, we considered the following variables: age, sex, onset of symptoms, education, laboratory results, and clinical signs and symptoms. Table 5 provides the final regression model, using 770 complete records to link specific data to SARS-COV-2 detection. We observed that leukopenia, monocytosis (%), eosinophil decrease %, onset of symptoms, increased CRP, presence of fever, decreased number of platelets,

medRxiv preprint doi: https://doi.org/10.1101/2020.10.22.20217851; this version posted October 26, 2020. The copyright holder for this preprint doi: https://doi.org/10.1101/2020.10.22.2021/1001/funder. who has granted beckber 20, 2020. The copyright holder for this perperint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

12

presence of anosmia/hyposmia, and body pain, in this specific order, were independent predictors for COVID-

19.

Table 4. Laboratory results from COVID-19 nasopharyngeal swab individuals attended from March 18 to April 8. 2020 at Polyclinic Piquet Carneiro. Rio de Janeiro

	Positive	Inconclusive	Undetected	р
Ν	410	94	763	
CRP m (Q1-Q3) ng/L	5.63 [2.32-13.49]	4.52 [1.72-11.27]	2.71 [1.12-7.37]	<0.0001 ^{a.c}
ALT m (Q1-Q3) µkat/L	0.37 [0.30-0.47]	0.35 [0.27-0.48]	0.30 [0.25-0.37]	<0.0001ª
AST m (Q1-Q3) µkat/L	0.37 [0.30-0.48]	0.35 [0.22-0.63]	0.30 [0.25-0.37]	<0.0001 ^{a.c}
Creatinine µmol/L	76.02±14.14	75.14±15.03	76.91±14.14	0.177
LDH ukat/L	3.05±7.62	3.10±8.77	2.95±7.65	0.031ª
CPK m (Q1-Q3) µkat/L	1.27 [094-1.91]	1.32 [0.89-1.95]	1.39 [0.95-2.09]	0.106
Ν	376	91	744	
Red cell 10 ¹² /L	4.8±0.4	4.8±0.5	4.8±0.5	0.834
Haemoglobin g/L	137±12	136±13	138±14	0.655
Haematocrit %	42±3.4	41.5±3.6	41.9±3.7	0.530
MCV fL	87.8±5.2	87.9±5.7	87.8±5.3	0.987
MCH pg/cell	28.7±1.8	28.8±2.3	28.8±2	0.609
MCMH g/L	326±10	328±10	328±10	0.064
RDW %	13.6±1.1	13.6±1.1	13.7±1.2	0.891
Leukocytes m [Q1-Q3] ×10 ⁹ /L	4,320 [3,620-5,360]	4,850 [4,000-6,520]	6,160 [4,985-7,445]	<0.0001 ^{a.c}
Neutrophils (%) m [Q1-Q3]	53 [45-63]	55 [49-65]	59 [52.5-65]	<0.0001 ^{a.c}
Neutrophils (Abs) m [Q1-Q3] ×10 ⁹ /L	2,379[1,827-3,353]	2,909 [2,161-4,116]	3,780 [2,799-4,781]	<0.0001 ^{a.c}
Lymphocytes (%) m [Q1-Q3]	34 [27-42]	34 [26-41]	31 [26-38]	<0.0001 ^{a.c}
Lymphocytes (Abs) m [Q1- Q3] ×10 ⁹ /L	1,580 [1,278±2,014]	1,920 [1,495±2,305]	2,057 [1,663±2,473]	<0.0001 ^{a.b.c}
Monocytes (%) m [Q1-Q3]	17 [12±7]	6 [12±8]	6 [4±8]	<0.0001 ^{a.b.c}
Monocytes (Abs) ×10 ⁹ /L	473±196	470±167	503±192	0.181
Eosinophils (%) m [Q1-Q3]	0 [0-5.5]	1 [0-2]	1 [0-2]	<0.0001ª
Eosinophils (Abs) m [Q1-Q3] 10ª/L	0 [0-41]	153 [0-44]	215 [0-7]	<0.0001 ^{a.b.c}
Basophils (%)	0±0.2	0±0	0±0	0.329
Platelets10 ⁹ /L	235±62	248±67	285±68	<0.0001 ^a

Data expressed as mean+- SD. compared with ANOVA or by median and interquartile m [Q1-Q3] and compared with Kruskal-Wallis test and Tukey or Dunn tests for multiple comparison. a- Detected vs Undetected. **b**- Detected vs Inconclusive and **c**- Undetected vs Inconclusive (p<0.05).

13

Variable Coef±SE Odds ratio 95%CI p Leukocytes -0.0005±0.0001 0.99 0.99-0.99 < 0.0001 1.1406±0.0334 1.07-1.22 < 0.0001 Monocytes (%) 1.15 Eosinophils (%) -0.0074±0.0016 0.99 0.98-0.99 < 0.0001 0.84 0.77-0.90 < 0.0001 Symptoms onset -0.1797±0.0406 1.00-1.02 C reactive protein 0.0106±0.0042 1.01 0.012 Fever 0.5158±0.2227 1.68 1.08-2.59 0.020 Platelets -0.0052±0.0017 0.99 0.99-0.99 0.003

0.5259±0.2438

0.4590±0.2301

Table 5. Logistic regression final with signs, symptoms and laboratory results independent predictors for detected COVID-19 in nasopharyngeal swab

Coef±SE: coefficient ± standard error

Anosmia or Hyposmia

Body pain

Symptoms and laboratory results for healthcare and non-healthcare personnel and their link to SARS-COV-2-positive SNF outcomes

1.05-2.73

1.01-2.48

0.031

0.046

1.69

1.58

CRP was significantly elevated in individuals with detectable SARS-COV-2, as shown in table 4 (reference value up to 8 mg/L), with this increase (93.5%) being more prominent in the HCP group.


LDH was slightly elevated, although within the reference range (2.25-3.75 μ kat/L), in SARS-COV-2-positive samples. An increase of 22% was observed in transaminases in SARS-CoV-2-positive samples from nonhealthcare personnel (Non-HCP) compared to a 28% increase in HCP; additionally, this increase remained within the reference range (ALT results up to 0.55 µkat/L in women and 0.68 µkat/L in men and AST results up to 0.53 μ kat/L in women and 0.63 μ kat/L in men are considered normal).

The mean total for the leukocytes decreased by 29%-32% in the presence of infection and was connected with reduced absolute neutrophil, lymphocyte, and eosinophil counts. However, there was a slight increase in the absolute monocyte counts in positive samples which coincided with a minor increase in the relative lymphocyte counts. Additionally, SARS-CoV-2-positive samples exhibited a 15%-22% reduction in their platelet count as well.

Detection of SARS-COV-2 in healthcare professionals and non-healthcare personnel as a function of time

There was a correlation between the frequency of SARS-COV-2 detection and the week of testing with the HCP incidence curve appearing to be parallel with the Non-HCP incidence curve (Figure 1).

Figure 1. COVID-19 results during the time interval (weeks). a) Frequency of detected. inconclusive and undetected results. b) Non Healthcare personnel vs Healthcare professionals detected COVID-19 frequency curves.



DISCUSSION

Although COVID-19 is known for its wide variety of clinical symptoms, we were able to identify some differences between casual and continuous reports. Findings of fever, anosmia or hyposmia, body pain, and chills were found to be linked to a 72% probability for a positive diagnosis, making these the most reliable clinical symptoms of infection.

Characteristics of patients

While this initiative was initially designed to support HCP at our institution, the dire need of expansive clinical support and diagnosis for COVID-19 meant that, from week two, we included patients from other public institutions and patients frequently treated at our facility in our testing cohort. This meant that while most of the individuals (80%) evaluated and tested at our site were HCP, 20% of the study cohort comprised Non-HCP patients.

15

The HCP group predominantly comprised self-identified white professionals (55.5%) with at least 12 years of study (80.1%) while only 42.2% of the individuals in the non-HCP group identified as white. The Non-HCP group had a higher frequency of obesity (11.1% vs 4.4%) compared to that in the HCP group which was reflected in the BMI values (Non-HCP: 29.2±6.0 vs HCP: 27.4±5.2). Additionally, smoking was also more frequent in the Non-HCP group, and there were also differences in adherence to the influenza vaccination scheduled between these two groups.

As of April 8, 2020, the deadline for data collection, Brazil had reported a total of 15,927 confirmed cases of COVID-19.[3] The State of Rio de Janeiro had 1,938 cases with this study representing 21.6% of all the cases reported in this state, with the majority of these cases being reported in HCP.

SARS-COV-2 nasopharyngeal swab results

Here, we noted that detection of the SARS-COV-2 RNA in NPS is associated with the onset of COVID-19 symptoms. This data is consistent with previous studies which identifies that the virus is detectable within the first eight days of symptoms [4,5] and reinforces the need for a differentiated strategy for determination of eligibility for NPS SARS-COV-2 testing, especially where the health system is constrained in terms of both human resources and the availability of test kits. Early recognition of COVID-19 is critical for the isolation of infected persons and the mitigation of community spread.[6] The ability to rule-out COVID-19 earlier enables more effective public health containment measures and frees up resources by reducing isolation time in suspected cases. Our study suggests that there is sufficient viral load to allow a positive NPS result within 3-4 days of infection, and this may significantly reduce isolation times, thus freeing up many valuable resources.

Headache, body ache, fever, anosmia or hyposmia, and chills were common symptoms and were more frequent among SARS-COV-2 NPS-positive patients than in SARS-COV-2 NPS-negative patients. These are wellknown signs and symptoms of various viral infections and COVID testing should be reliant on a combination of these symptoms and a comprehensive understanding of the patients' local, regional, and travel history especially in resource-constrained conditions. HCP should treat any patient with these symptoms and a high likelihood of exposure as SARS-CoV-2-positive even in the absence of an appropriate test. Zhang et al.[7]

16

observed fever (91.7%), cough (75.0%), fatigue (75.0%), and gastrointestinal symptoms (39.6%) in their COVID-19 cohort. In a meta-analysis, Li and colleagues [5] reported that fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%) were all primary indicators of COVID-19. In this study, we also investigated if the combination of signs and symptoms could help in developing a decisionmaking rationale for ordering laboratory tests. Curiously, an increase in the frequency of anxiety and "difficulty in swallowing" was observed among those patients with inconclusive SARS-COV-2 NPS results. Psychological aspects and global mental health have already been the subject of a number of studies, as the mental toll of the patient becomes more evident.[8-10] In China, more than 70% of the patients experience moderate to high levels of psychological symptoms, specifically elevated scores for obsessive compulsion, interpersonal sensitivity, phobic anxiety, and psychoticism.[11] Our results did not corroborate those of Zhang and colleagues [12], who showed a higher prevalence of insomnia (38.4% vs. 30.5%, p < 0.01) and anxiety (13.0%) vs. 8.5%, p < 0.01) in Non-HCP (n = 1,255) patients, while we found no differences in the prevalence of anxiety between HCP and Non-HCP in our study. This may be due to the methodology used, as this study was not designed to compare these two groups. It is not possible to further characterize the work and professional activity of our participants but it is worth noting that there have been other studies that have identified differences in anxiety and stress among medical and nursing staff [13].

Anosmia is a frequent symptom [14] of COVID-19 and is often the only indicator in asymptomatic carriers.[15] This symptom is transient and it has been suggested that this anosmia is linked to the destruction of the epithelial cells in the nose. These cells have a high expression of angiotensin converting enzyme 2, the receptor for SARS-CoV-2, which allows the virus to penetrate the system.[16]

Dyspnea is a well-characterized symptom of COVID-19 and has been shown to be closely related to the severity of the disease and mortality rates.[17,18] Our study did not evaluate disease severity, but rather focused on identification of clinical and laboratory data that could be used to predict COVID-19 infection in HCP, in an effort to allow for their rapid isolation to prevent wide spread infections among the hospital staff. Our results showed that anosmia / hyposmia (p < 0.0001), fever (p < 0,0001), body pain (p < 0.0001), and chills (p = 0.001), in this specific order, were independent predictors for SARS-COV-2 NSF detection. Moreover, the

17

combination of these symptoms has a prognostic capacity of around 72% for SARS-COV-2. This information should guide healthcare workers in determining the course of evaluations including laboratory testing, while allowing for the fact that the COVID-19 pandemic may contribute to revisions in the State and Municipal health authority guidelines for clinical testing and isolation.

The laboratory results indicate that the total leukocytes, % of monocytes, eosinophils, RCP, and platelet counts were all independent predictors of COVID-19. These factors were also identified in several previous COVID-19 studies.[5 19 20] In this study, we were able to combine signs, symptoms, and laboratory results in a logistic regression analysis that identified various independent predictor values that could be used to supplement RT-PCR testing in resource scarce environments. Leukocyte counts of under 5,400/µL, relative monocytosis (>9%), eosinopenia, and elevated RCP within the first seven days from the onset of fever, anosmia / hyposmia, and body pain were the main independent variables associated with positive RT-PCR results. Although platelets also appeared to be an independent predictor, the range for this value remained within the clinical reference values and would need to be compared with previous results from the same patient to be of a significant value. Additionally, the cut-off points for leukocyte counts and percentage of monocytes may also guide the interpretation of the complete blood cell count during the first days of infection. Additionally, these results may also be used during follow-up for hospitalized patients when AST, ALT, gamma-GT, LDH, and alpha-HBDH are all markedly altered [21].

The risk factors reported here may be used in future studies to evaluate associated medical interventions, hospitalization, and mortality rates. This cohort should also be expanded and new longitudinal evaluations should be undertaken to better understand the condition of these patients in a post pandemic future. Nonetheless, we were able to confirm a greater risk for infection in HCP. It is well known that HCP are subject to far greater continuous exposure to COVID-19 than the general public, thus increasing their infection rates. Noteworthy, this screening started at the beginning of the epidemic in Brazil and that the number of detected cases in this study retained a linear scale, suggesting that early infections with COVID-19 were more prevalent among HCP and for this reason close monitoring of this population might be crucial to reducing the burden on the healthcare system.

18

This study has several limitations associated with the fact that it is a cross-sectional, ongoing study, with an increasing number of patients. Although limited in number, data here may support other studies so that in the long term a better meta-analysed prediction system can be developed. The HCP population is predominantly made up of younger people and this may cause differences in the observations of this study versus studies conducted in older populations.[22 23] Currently, laboratory-based RT-PCR is the recommended test for diagnoses of acute cases to ensure patients can be identified and isolated and to facilitate the public health response, as reviewed by Venter and Richter {Venter, 2020 #1796}. On the other hand, The false-negative results may lead to misdiagnoses in both patients and HCP, with increased risk of infection transmission {Payne, 2020 #1795}. So, combining routine laboratory test that can detect both acute phase proteins and specific altered leukocyte profile corresponding to COVID-19 infection could add parameters to more efficient control of suspected individuals. Nonetheless, the rapid development of point-of-care molecular or antigen tests are already a reality {Lippi, 2020 #1468}

Up to May. 2020, the clinical diagnosis and medical intervention for COVID-19 has been restricted in HCP servicing the military, civil, and federal police reaching 1,626 confirmed cases.

In conclusion, positive SARS-COV-2 NPS assays were associated with fever, anosmia or hyposmia, body pain, and chills, and patients were all positive within the first 3-8 days after symptom onset. Elevated CRP, leukocyte counts under 5,400 / μ L, and relative monocytosis (>9%) were all common among patients with COVID-19. These parameters may help to identify and isolate probable SARS-CoV-2 infections in the absence of RT-PCR tests.

Key message

- Healthcare professionals (HCP) working at the frontline are among the groups most affected by the COVID-19 pandemic. We investigated the clinical features of 1,297 individuals, mostly (80%) HCP, who tested positive for the SARS-CoV-2 (COVID-19) during the period immediately following the pandemic declaration in Brazil (March 19 to April 8, 2020).
- Signs and symptom data and blood samples were collected for all individuals who were tested for SARS-CoV-2 by RT-PCR assays in nasopharyngeal swab (NPS).
- CRP, LDH, AST, and ALT were elevated among COVID-19-infected individuals, and leukometry differed between individuals within the different SARS-COV-2 NPS detection results. Anosmia/hyposmia, fever, body pain, and chills, in this specific order, were independent predictors for COVID-19. The estimated

probability of COVID-19 detection when all four of these signs and symptoms were present was 72%. There was a trend of increasing number of SARS-CoV-2-positive test results in later weeks of analysis especially in HCP samples.

Here, we identified that the significant clinical features of SARS-CoV-2 in Brazil included anosmia, fever, chills, body pain, elevated CRP, leukocytes under 5,400 x 10⁹/L, and relative monocytosis (>9%). These variables may help, in the absence of RT-PCR tests, to monitor the COVID-19 infection rate during a pandemic.

Declaration of interest

None to declare.

Funding.

Rio de Janeiro Research Support Agency (FAPERJ), National Council Research (CNPq). The Laboratory of Histocompatibility and Cryopreservation received a thermocycler and a -80C freezer from COVID-19 donation open account for Pedro Ernesto University Hospital. Rio de Janeiro Health Secretary provided nucleic acid extraction and RT-PCR kits.

Authors contribution:

Study conception and design: L.C. Porto, R. Rufino, C.H. Costa, A. S. Nunes and I. Bouzas

Interview, Consultation and Patient orientation and NPS and blood sampling: A. S. Nunes, T. C. Ferreira, A.C. Faria, F.H. Silva, C. A. Duarte, S. Vilas Boas

Laboratory testing and interpretation: D.A. Secco, A. M. G. Santos, R. S. Menezes, V. M. A. Souza, V. M. Porto, J. R. Mota, A. P. Villela-Silva, M. V. Castro, J. S. Nogueira, F. M. Vasconcelos, A. D. Silva, C. V. Lima and N. B. Brazão, I. A.A. Brito, S. B. Costa, R. M. R. Lemes, J. I. O. dePaula, G. L. Bongionanni, O. C. L. Bezerra, V. V. Andrade-Neto, L. Morette.

Electronic Data Acquisition: S.M. Freire, I. Bouzas, R. Souza.

Logistic, Communication and Supply services: E. P. Bittencourt, A. V. Loureiro, R. S. Barboza, J. A L. Sanches, D. P. Felizardo, A. V. Rodrigues, P. A. Franco, R. Miranda

Analysis of data and figures: R. A. G. Martins, I. Bouzas, R. Rufino, C. H. Costa and L.C. Porto

Interpretation of data: I. Bouzas, R. Rufino, C. H. Costa and L.C. Porto

Drafting of manuscript: L. C. Porto, R. Rufino and C. H. Costa.

Critical revision: C. H. Costa and I. Bouzas

All authors approved the final manuscript.

Acknowledgments:

We thank all team at the front line for reception of patients, security and cleaning services. Undergraduate, interns and residents acting as volunteers were also deeply acknowledge. We also thank Carlos Nunes, Andrea Benazzi, Karina Goulart, Tainah Lima, Miguel Garcia, Breno Sampaio and Marcos Alcoforado for data entry and Mário João Junior for electronic entry data

development. We would like to thank Ana Clara Perrone and Editage (www.editage.com) for English language editing.

References

- 1. WHO. Coronavirus disease (COVID-19) outbreak situation. In: Organization WH, ed., 2020.
- Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020;395(10231):1225-28 doi:
 - 10.1016/S0140-6736(20)30627-9[published Online First: Epub Date]].
- 3. MH. Ministry of Health, 2020.
- 4. Cheng VCC, Wong SC, Chen JHK, et al. Escalating infection control response to the rapidly evolving epidemiology of the Coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol 2020:1-24 doi: 10.1017/ice.2020.58[published Online First: Epub Date]].
- 5. Li LQ, Huang T, Wang YQ, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol 2020 doi: 10.1002/jmv.25757[published Online First: Epub Date]].
- 6. Amrane S, Tissot-Dupont H, Doudier B, et al. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot. Travel Med Infect Dis 2020:101632 doi: 10.1016/j.tmaid.2020.101632[published Online First: Epub Date]].
- 7. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 doi: 10.1111/all.14238[published Online First: Epub Date]].
- 8. Ahmed MZ, Ahmed O, Aibao Z, Hanbin S, Siyu L, Ahmad A. Epidemic of COVID-19 in China and associated Psychological Problems. Asian J Psychiatr 2020;**51**:102092 doi: 10.1016/j.ajp.2020.102092[published Online First: Epub Date]|.
- 9. Chew NWS, Lee GKH, Tan BYQ, et al. A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak. Brain Behav Immun 2020 doi: 10.1016/j.bbi.2020.04.049[published Online First: Epub Date].
- 10. Tsamakis K, Rizos E, A JM, et al. COVID-19 pandemic and its impact on mental health of healthcare professionals. Ther Med 2020;19(6):3451-53 Exp doi: 10.3892/etm.2020.8646[published Online First: Epub Date]|.
- 11. Tian F, Li H, Tian S, Yang J, Shao J, Tian C. Psychological symptoms of ordinary Chinese citizens based on SCL-90 during the level I emergency response to COVID-19. Psychiatry Res 2020;288:112992 doi: 10.1016/j.psychres.2020.112992[published Online First: Epub Date]].
- 12. Zhang WR, Wang K, Yin L, et al. Mental Health and Psychosocial Problems of Medical Health Workers during the COVID-19 Epidemic in China. Psychother Psychosom 2020:1-9 doi: 10.1159/000507639[published Online First: Epub Date]].
- 13. Huang Y, Zhao N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional survey. Psychiatry Res 2020;288:112954 doi: 10.1016/j.psychres.2020.112954[published Online First: Epub Date]|.
- 14. Hopkins C, Surda P, Kumar N. Presentation of new onset anosmia during the COVID-19 pandemic. Rhinology 2020 doi: 10.4193/Rhin20.116[published Online First: Epub Date]].
- 15. Marinosci A, Landis BN, Calmy A. Possible link between anosmia and COVID-19: sniffing out the truth. Eur Arch Otorhinolaryngol 2020 doi: 10.1007/s00405-020-05966-0[published Online First: Epub Date]].
- 16. Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 2020 doi: 10.1038/s41591-020-0868-6[published Online First: Epub Date]|.

- 17. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020:101623 doi: 10.1016/j.tmaid.2020.101623[published Online First: Epub Date]|.
- 18. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect 2020 doi: 10.1016/j.jinf.2020.04.021[published Online First: Epub Date]|.
- 19. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020 doi: 10.1515/cclm-2020-0198[published Online First: Epub Date].
- 20. Fan BE, Chong VCL, Chan SSW, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol 2020 doi: 10.1002/ajh.25774[published Online First: Epub Date]].
- 21. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020 doi: 10.1093/cid/ciaa247[published Online First: Epub Date]|.
- 22. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with and middle-aged patients. Infect 2020 doi: young Т 10.1016/j.jinf.2020.03.005[published Online First: Epub Date]|.
- 23. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med 2020 doi: 10.1164/rccm.202003-0543OC[published Online First: Epub Date]|.